Evaluation of Nurses' and Patients' Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR): A French Observational Study.
Fiche publication
Date publication
juillet 2020
Journal
Advances in therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume
Tous les auteurs :
Delemer B, Nguyen-Tan-Hon T, Coriat R, Smith D, Schillo F, Raingeard I, Sobhani I, Etienne PL, Decoudier B, Bisot-Locard S, Santos A, Raverot G, Cadiot G
Lien Pubmed
Résumé
The first long-acting release (LAR) formulation of octreotide was marketed in France in the late 1990s. An injectable formulation of Sandostatin LAR (Novartis SAS) with a new diluent has been developed to facilitate its preparation and administration and to improve its use in practice.
Mots clés
Acromegaly, Neuroendocrine tumors, Nurses, Patients, Quality of life, Satisfaction, Somatostatin LAR
Référence
Adv Ther. 2020 Jul 18;: